Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

NEXT STORY
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PREV STORY
Microcarriers Market Size to Reach USD 2.9 Billion in 2028; One of the leading drivers for microcarriers market growth is rising prevalence of diseases where cell therapy can be effectively applied | Reports And Data
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Renalytix Reports Full Year Fiscal 2021 Results

author_avatar
NASDAQ Market News

U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection

author_avatar
NASDAQ Market News

Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from ...

author_avatar
NASDAQ Market News